Health Economics and Value

Demonstrate your product’s value.

Deliver the right evidence to demonstrate your product’s value and address regulator and payer requests efficiently.
Contact Us
Solutions Real World Evidence Health Economics and Value
En savoir plus

Demonstrate value

Generate the evidence you need to go from research to market, overcome regulatory hurdles, or support payer approval.

Partner with IQVIA to access health economic modeling solutions to support market-specific reimbursement, market access and high-impact scientific publications.

Beyond data and insights, work with our local experts to help you manage health technology assessment bodies’ requirements around the world to shorten timeframes and reduce costs and operational burdens.

Accelerate your results with:

Global network

An international network that can deliver local solutions with global oversight, including expertise about the new EU HTA Regulation.

Patient-level data

Access to the world's most comprehensive non-identified patient-level data and the ability to leverage real world evidence in health economic modeling.

Domain expertise

Therapeutic and cross functional expertise (R&D, PMA, Epi, etc.) for scientifically rigorous and commercially relevant solutions.

150,000+

Data suppliers

~26M

Healthcare professionals

60+

Petabytes of unique data

~1M

Data feeds

1.2B+

Non-identified patient records

400,000+

Sources of social media

New ways to generate evidence for outcomes research

Optimize your outcomes research with validated, representative, relevant results. Generate actionable insights with solutions that apply innovative data collection techniques and cross-link de-identified data to close data gaps.

Advantages include:

  • Classic observational, low interventional clinical studies and innovative approaches such as enriched studies
  • Advanced analytics enhance the ability to determine and quantify benefits, risks, and outcomes
  • A strong track record in EMA-accepted Drug Utilization Studies (DUS) in multiple therapy areas and geographies, and experience in working with the FDA, ENCePP, EUnetHTA, and MHRA

Evolving market access rules demand agile responses

Health technology assessment processes and pricing rules are shifting, so previous approaches might no longer deliver the results you expect. Follow our new series of podcasts and blogs to stay informed about latest changes in market access and their impact on your approaches. Get early insight on trends to help you be prepared for what’s next.

Discover insights

Learn More

white paper
The Evolving Role of Real-World Evidence in Oncology HTA Decision-Making: Opportunities and Challenges

White Paper
EU HTA in action

How Health Technology Developers can prepare for a successful JCA
Fact Sheet
Comparative evidence for EU HTA

Partner with IQVIA to conduct best-in-class indirect treatment comparison programs

Insight Brief
Joint Scientific Consultations

Getting the most from Early Scientific Advice
Insight Brief
The first step on a long road ahead

A deep dive into the JCA Implementing Act
Fact Sheet
Market Access Insights

A clearer path to Market Access
Blog
How Emerging Biopharma Companies Can Prepare for EU HTA

Publication
IQVIA RWE Bibliography

With a history of 25 years and more than 5,200 publications and presentations, our bibliography captures real world insights into patients, diseases, treatments, outcomes and costs across virtually all therapeutic areas and projects completed in more than 50 countries.
WHITE PAPER
Journey into the Whirlwind

Post-COVID pricing and evidence policy changes and their implications for development and commercialization
White Paper
The future of EU HTA

How pharmaceutical companies can prepare for the new process
White Paper
Assessing person-centered therapeutic innovations

Are usage experience and outcome benefits from person-centered therapeutic innovations appropriately valued?

Prev
Next

Related solutions

Market Access Insights

Market Access Insights provides access to HTA, reimbursement, regulatory, clinical trial, and pricing information so that you can make more informed market access decisions.

Study Design

Use emerging data sources and advances in evidence methods to demonstrate product value and safety.

Contact Us